undamentalytics Newsletter
Sign in

Inhibrx Biosciences, Inc. key statistics and ratios

In fiscal 2025, Inhibrx Biosciences, Inc. had return on equity of -197.8%, an operating margin of -10386.5%, debt equal to 1258.1% of equity and a current ratio of 3.93. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025
Operating margin<−999%<−999%<−999%
Net margin<−999%>999%<−999%
Free-cash-flow margin<−999%<−999%<−999%
Return on equity——−197.8%
Return on assets−78.4%690.7%−85.6%
Asset turnover0.010.000.01
Current ratio5.253.943.93
Debt to equity475.8%0.0%>999%
Interest cover (operating income ÷ interest)n/mn/mn/m
Effective tax rate—0.0%—
R&D as % of revenue>999%>999%>999%
Capital spending as % of revenue255.2%>999%2.4%
Free cash flow ÷ net income—−11.7%—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 5 checks passed · June 30, 2026
What it owns · $154m
Short-term assets $142mLonger-term assets $12m
What it owes, and who funded it · $207m
Short-term liabilities $28mLonger-term liabilities $179mShareholders' equity $-53m
  • Short-term assets cover short-term liabilities $142m of assets due within a year against $28m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $142m short-term assets against $179m of longer-dated liabilities.
  • More cash than debt $133m of cash against $176m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$132m of operating cash flow against $176m of debt.
  • Operating profit covers interest at least five times over Operating income of −$128m against $16m of interest.

From Inhibrx Biosciences, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: DARE vs INBXINBX vs LGVNINBX vs RNAC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inhibrx Biosciences, Inc.